Jazz Pharmaceuticals (JAZZ) News $JAZZ
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
SmarTrend Watching for Potential Rebound in Shares of Jazz Pharmaceuticals After 4.26% Loss
Comtex SmarTrend(R) - Fri Mar 21, 4:20PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $143.65 to a high of $151.99. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $148.31 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Horizon Pharma To Buy Vidara, Join Exodus To Ireland
at Investor's Business Daily - Wed Mar 19, 9:45AM CDT
Horizon Pharma (HZNP) followed many of its fellow drugmakers to Ireland Wednesday as it agreed to buy Dublin-based Vidara Therapeutics in a deal worth $660 million. Horizon shares jumped 17% in the stock market today, hitting an all-time high....
5 Big Health Care Stocks to Trade for Gains
at The Street - Tue Mar 18, 8:56AM CDT
Health care stocks are looking, well, healthy right now. And that's creating some big trading opportunities this month.
Jim Cramer: This Froth Has to Be Reined In
at The Street - Mon Mar 17, 10:32AM CDT
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.
Jazz Pharmaceuticals Earnings Review: 20 Days after Announcement Shares Down 14.7% (JAZZ)
Comtex SmarTrend(R) - Mon Mar 17, 7:11AM CDT
When Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings 20 days ago on February 25th, 2014, analysts, on average, expected the company to report earnings of $1.78 on sales of $237.5 million. The company actually reported EPS of $1.72 on sales of $235.8 million, missing EPS estimates by $0.06 and missing revenue estimates by $1.7 million. Shares of Jazz Pharmaceuticals have slipped from $174.98 to $149.22, representing a loss of 14.7%, since the company reported earnings 20 days ago.
Stocks Pile On Losses; Jazz Breaks Support
at Investor's Business Daily - Thu Mar 13, 12:32PM CDT
Stocks have vastly worsened Thursday afternoon, with the major indexes sporting losses of about 1% or more. The Nasdaq swooned 1.3% and the S&P 500 slumped 0.9%. The Dow Jones industrial average shed 1.2%, with 27 of 30 issues lower. Turnover was...
Stocks Open To Modest Gains; Amazon Jumps On Prime Price Hike
at Investor's Business Daily - Thu Mar 13, 9:34AM CDT
Stocks flew straight and level in early trade Thursday, with the Nasdaq, S&P 500 and the Dow Jones industrial average all holding 0.2% gains. Trading was quiet, down 15% on the Nasdaq and 19% lower on the NYSE, compared with the same time Wednesday....
A Brief History Of 21st Century Stock Leadership
at Investor's Business Daily - Wed Mar 12, 5:24PM CDT
Here's a short list of short lists of leading stocks. In May 2003, Investor's Business Daily launched the IBD 100. The feature each week zeroed in on 100 leading stocks -- the best of the best among leaders, aimed at saving investors time by culling...
SmarTrend Watching for Potential Pullback in Shares of Jazz Pharmaceuticals After 3.97% Gain
Comtex SmarTrend(R) - Wed Mar 12, 3:57PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $150.36 to a high of $159.88. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $157.23 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
How To Invest: Seek Stock Ideas In Sector Leaders
at Investor's Business Daily - Tue Mar 11, 4:23PM CDT
Every great trade begins with a great idea. While there's a wealth of places in IBD to get great ideas for your watch list, one feature that investors must check out is Sector Leaders. Published today on Page B1, the Sector Leaders are the top-rated...
Jazz Pharmaceuticals Earnings In Retrospect: Down 11.3% in the Last 13 Days (JAZZ)
Comtex SmarTrend(R) - Mon Mar 10, 7:58AM CDT
When Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings 13 days ago on February 25th, 2014, analysts, on average, expected the company to report earnings of $1.78 on sales of $237.5 million. The company actually reported EPS of $1.72 on sales of $235.8 million, missing EPS estimates by $0.06 and missing revenue estimates by $1.7 million. Since the company's report, shares of Jazz Pharmaceuticals have fallen from $174.98 to $155.24, representing a loss of 11.3% in the past 13 days.
Nasdaq Lags As Stock Market Closes Lower
at Investor's Business Daily - Fri Mar 07, 3:28PM CST
Stocks closed mixed as a better-than-expected jobs report failed to hold the market's interest. Indexes opened higher after the Labor Department reported an increase of 175,000 jobs in February, while the unemployment rate edged up to 6.7%. But the...
Stocks Open Higher, Turn Mixed After Employment Report
at Investor's Business Daily - Fri Mar 07, 9:31AM CST
Stocks opened higher Friday, then backtracked to mixed terrain as drugmakers and some leading stocks added drag in early trade. The Dow Jones industrial average remained ahead 0.4%. The S&P 500 was up 0.2% and the Nasdaq slipped 0.2%. Celgene (CELG),...
Stock Market Closes Mixed; Ambarella Tops Expectations
at Investor's Business Daily - Thu Mar 06, 4:00PM CST
Stocks closed mixed Thursday, and after the bell Ambarella (AMBA) topped profit expectations. Ambarella, a maker of video chips, reported a 27% jump in sales to $40 million for the January-ended quarter. Adjusted earnings of 26 cents a share were...
Stock Market Closes Mixed; Medical Leaders Drop
at Investor's Business Daily - Thu Mar 06, 3:13PM CST
Stocks closed mixed Thursday as the medical sector, one of the market's bulwarks, came under some selling. The Dow Jones industrial average led with a 0.4% gain, while the S&P 500 added 0.2% and the Nasdaq fell 0.2%. Volume fell across the board,...
Insider Trading Alert - IP, CYBX And JAZZ Traded By Insiders
at The Street - Thu Mar 06, 1:00PM CST
Stocks with insider trader activity include IP, CYBX and JAZZ
MacroGenics Appoints Matthew Fust to Its Board of Directors
GlobeNewswire - Thu Mar 06, 6:09AM CST
MacroGenics, Inc. (Nasdaq:MGNX) today announced that its Board of Directors is increasing its size from seven to eight members and that Matthew Fust has been appointed to fill the vacancy. Mr. Fust joins the Board and becomes Chairman of its Audit Committee, effective immediately. Mr. Fust will serve as a Class II Director, with Class II having a term expiring at the annual meeting of stockholders to be held in 2015.
Gentium S.p.A. Announces Decision to Voluntarily Delist American Depositary Shares from The NASDAQ Global Market
GlobeNewswire - Wed Mar 05, 1:50PM CST
Gentium S.p.A. (Nasdaq:GENT), a Jazz Pharmaceuticals company, today announced that it has notified the NASDAQ Stock Market of its intention to voluntarily delist its American Depositary Shares (ADSs) from The NASDAQ Global Market.
New Government in Italy: How Will It Affect These Italian ADRs?
Louie Grint, The Motley Fool - Motley Fool - Tue Mar 04, 1:38PM CST
As you probably heard, after the breakup of the government coalition that was ruling Italy, Matteo Renzi became the new prime minister in the country. Well, he just took office on Saturday and designated Pier Carlo Padoan, chief economist at the...
Biotechs, Medicals Get Hurt Amid Price-Inquiry News
at Investor's Business Daily - Fri Mar 21, 5:26PM CDT
Two normally healthy biotech stocks suffered critical declines Friday, while most other medical names on the IBD 50 remained in fairly stable condition. Still, the biotech illness spread to other drug stocks. As a result, six of the seven biggest...
SmarTrend Watching for Potential Rebound in Shares of Jazz Pharmaceuticals After 4.26% Loss
Comtex SmarTrend(R) - Fri Mar 21, 4:20PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $143.65 to a high of $151.99. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $148.31 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Horizon Pharma To Buy Vidara, Join Exodus To Ireland
at Investor's Business Daily - Wed Mar 19, 9:45AM CDT
Horizon Pharma (HZNP) followed many of its fellow drugmakers to Ireland Wednesday as it agreed to buy Dublin-based Vidara Therapeutics in a deal worth $660 million. Horizon shares jumped 17% in the stock market today, hitting an all-time high....
5 Big Health Care Stocks to Trade for Gains
at The Street - Tue Mar 18, 8:56AM CDT
Health care stocks are looking, well, healthy right now. And that's creating some big trading opportunities this month.
Jim Cramer: This Froth Has to Be Reined In
at The Street - Mon Mar 17, 10:32AM CDT
The public market is currently divorced from the dazzling IPOs -- and that's always a bad sign.
Jazz Pharmaceuticals Earnings Review: 20 Days after Announcement Shares Down 14.7% (JAZZ)
Comtex SmarTrend(R) - Mon Mar 17, 7:11AM CDT
When Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings 20 days ago on February 25th, 2014, analysts, on average, expected the company to report earnings of $1.78 on sales of $237.5 million. The company actually reported EPS of $1.72 on sales of $235.8 million, missing EPS estimates by $0.06 and missing revenue estimates by $1.7 million. Shares of Jazz Pharmaceuticals have slipped from $174.98 to $149.22, representing a loss of 14.7%, since the company reported earnings 20 days ago.
Stocks Pile On Losses; Jazz Breaks Support
at Investor's Business Daily - Thu Mar 13, 12:32PM CDT
Stocks have vastly worsened Thursday afternoon, with the major indexes sporting losses of about 1% or more. The Nasdaq swooned 1.3% and the S&P 500 slumped 0.9%. The Dow Jones industrial average shed 1.2%, with 27 of 30 issues lower. Turnover was...
Stocks Open To Modest Gains; Amazon Jumps On Prime Price Hike
at Investor's Business Daily - Thu Mar 13, 9:34AM CDT
Stocks flew straight and level in early trade Thursday, with the Nasdaq, S&P 500 and the Dow Jones industrial average all holding 0.2% gains. Trading was quiet, down 15% on the Nasdaq and 19% lower on the NYSE, compared with the same time Wednesday....
A Brief History Of 21st Century Stock Leadership
at Investor's Business Daily - Wed Mar 12, 5:24PM CDT
Here's a short list of short lists of leading stocks. In May 2003, Investor's Business Daily launched the IBD 100. The feature each week zeroed in on 100 leading stocks -- the best of the best among leaders, aimed at saving investors time by culling...
SmarTrend Watching for Potential Pullback in Shares of Jazz Pharmaceuticals After 3.97% Gain
Comtex SmarTrend(R) - Wed Mar 12, 3:57PM CDT
Jazz Pharmaceuticals (NASDAQ:JAZZ) traded in a range yesterday that spanned from a low of $150.36 to a high of $159.88. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $157.23 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
How To Invest: Seek Stock Ideas In Sector Leaders
at Investor's Business Daily - Tue Mar 11, 4:23PM CDT
Every great trade begins with a great idea. While there's a wealth of places in IBD to get great ideas for your watch list, one feature that investors must check out is Sector Leaders. Published today on Page B1, the Sector Leaders are the top-rated...
Jazz Pharmaceuticals Earnings In Retrospect: Down 11.3% in the Last 13 Days (JAZZ)
Comtex SmarTrend(R) - Mon Mar 10, 7:58AM CDT
When Jazz Pharmaceuticals (NASDAQ:JAZZ) reported earnings 13 days ago on February 25th, 2014, analysts, on average, expected the company to report earnings of $1.78 on sales of $237.5 million. The company actually reported EPS of $1.72 on sales of $235.8 million, missing EPS estimates by $0.06 and missing revenue estimates by $1.7 million. Since the company's report, shares of Jazz Pharmaceuticals have fallen from $174.98 to $155.24, representing a loss of 11.3% in the past 13 days.
Nasdaq Lags As Stock Market Closes Lower
at Investor's Business Daily - Fri Mar 07, 3:28PM CST
Stocks closed mixed as a better-than-expected jobs report failed to hold the market's interest. Indexes opened higher after the Labor Department reported an increase of 175,000 jobs in February, while the unemployment rate edged up to 6.7%. But the...
Stocks Open Higher, Turn Mixed After Employment Report
at Investor's Business Daily - Fri Mar 07, 9:31AM CST
Stocks opened higher Friday, then backtracked to mixed terrain as drugmakers and some leading stocks added drag in early trade. The Dow Jones industrial average remained ahead 0.4%. The S&P 500 was up 0.2% and the Nasdaq slipped 0.2%. Celgene (CELG),...
Stock Market Closes Mixed; Ambarella Tops Expectations
at Investor's Business Daily - Thu Mar 06, 4:00PM CST
Stocks closed mixed Thursday, and after the bell Ambarella (AMBA) topped profit expectations. Ambarella, a maker of video chips, reported a 27% jump in sales to $40 million for the January-ended quarter. Adjusted earnings of 26 cents a share were...
Stock Market Closes Mixed; Medical Leaders Drop
at Investor's Business Daily - Thu Mar 06, 3:13PM CST
Stocks closed mixed Thursday as the medical sector, one of the market's bulwarks, came under some selling. The Dow Jones industrial average led with a 0.4% gain, while the S&P 500 added 0.2% and the Nasdaq fell 0.2%. Volume fell across the board,...
Insider Trading Alert - IP, CYBX And JAZZ Traded By Insiders
at The Street - Thu Mar 06, 1:00PM CST
Stocks with insider trader activity include IP, CYBX and JAZZ
MacroGenics Appoints Matthew Fust to Its Board of Directors
GlobeNewswire - Thu Mar 06, 6:09AM CST
MacroGenics, Inc. (Nasdaq:MGNX) today announced that its Board of Directors is increasing its size from seven to eight members and that Matthew Fust has been appointed to fill the vacancy. Mr. Fust joins the Board and becomes Chairman of its Audit Committee, effective immediately. Mr. Fust will serve as a Class II Director, with Class II having a term expiring at the annual meeting of stockholders to be held in 2015.
Gentium S.p.A. Announces Decision to Voluntarily Delist American Depositary Shares from The NASDAQ Global Market
GlobeNewswire - Wed Mar 05, 1:50PM CST
Gentium S.p.A. (Nasdaq:GENT), a Jazz Pharmaceuticals company, today announced that it has notified the NASDAQ Stock Market of its intention to voluntarily delist its American Depositary Shares (ADSs) from The NASDAQ Global Market.
New Government in Italy: How Will It Affect These Italian ADRs?
Louie Grint, The Motley Fool - Motley Fool - Tue Mar 04, 1:38PM CST
As you probably heard, after the breakup of the government coalition that was ruling Italy, Matteo Renzi became the new prime minister in the country. Well, he just took office on Saturday and designated Pier Carlo Padoan, chief economist at the...
